Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar,
Received FDA Approval for Treating Different Forms of Inflammato ry
Diseases

Vinod   Kumar   Rajana; Sudha   Madhavi   Penumaka; Cevella      Saritha; Velayutham      Ravichandiran; Debabrata      Mandal

doi:10.2174/0118715230273701231102100558

« Previous Next »

Graphical Abstract

[1]
 Yuflyma FDA approval history.   Available from: https://www.drugs.com/history/yuflyma.html

[2]
Lim, H.; Lee, S.; Lee, H.; Lee, J.; Son, J.; Shin, W.; Heo, Y.S. Structural biology of the tnfα antagonists used in the treatment of rheumatoid arthritis. Int. J. Mol. Sci.,  2018, 19(3), 768.
 [http://dx.doi.org/10.3390/ijms19030768] [PMID:  29518978]

[3]
Hu, S.; Liang, S.; Guo, H.; Zhang, D.; Li, H.; Wang, X.; Yang, W.; Qian, W.; Hou, S.; Wang, H.; Guo, Y.; Lou, Z. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J. Biol. Chem.,  2013, 288(38), 27059-27067.
 [http://dx.doi.org/10.1074/jbc.M113.491530] [PMID:  23943614]

[4]
Tran, B.N.; Chan, S.L.; Ng, C.; Shi, J.; Correia, I.; Radziejewski, C.; Matsudaira, P. Higher order structures of Adalimumab, Infliximab and their complexes with TNFα revealed by electron microscopy. Protein Sci.,  2017, 26(12), 2392-2398.
 [http://dx.doi.org/10.1002/pro.3306] [PMID:  28940886]

[5]
Wysocki, T.; Paradowska-Gorycka, A. Pharmacogenomics of anti-TNF treatment response marks a new era of tailored rheumatoid arthritis therapy. Int. J. Mol. Sci.,  2022, 23(4), 2366.
 [http://dx.doi.org/10.3390/ijms23042366] [PMID:  35216481]

[6]
Nguyen, DX.; Ehrenstein, MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J. Exp. Med.,  2017, 213(7), 1241-1253.
 [http://dx.doi.org/10.1084/jem.20151255]

[7]
Roach, D.R.; Bean, A.G.D.; Demangel, C.; France, M.P.; Briscoe, H.; Britton, W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol.,  2002, 168(9), 4620-4627.
 [http://dx.doi.org/10.4049/jimmunol.168.9.4620] [PMID:  11971010]

[8]
Kay, J.; Jaworski, J.; Wojciechowski, R.; Wiland, P.; Dudek, A.; Krogulec, M.; Jeka, S.; Zielinska, A.; Trefler, J.; Bartnicka-Maslowska, K.; Krajewska-Wlodarczyk, M.; Klimiuk, P.A.; Lee, S.J.; Bae, Y.J.; Yang, G.E.; Yoo, J.K.; Furst, D.E.; Keystone, E. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res. Ther.,  2021, 23(1), 51.
 [http://dx.doi.org/10.1186/s13075-020-02394-7] [PMID:  33546755]

[9]
Furst, D.E.; Jaworski, J.; Wojciechowski, R.; Wiland, P.; Dudek, A.; Krogulec, M.; Jeka, S.; Zielinska, A.; Trefler, J.; Bartnicka-Maslowska, K.; Krajewska-Wlodarczyk, M.; Klimiuk, P.A.; Lee, S.J.; Kim, S.H.; Bae, Y.J.; Yang, G.E.; Yoo, J.K.; Kay, J.; Keystone, E. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology.,  2022, 61(4), 1385-1395.
 [http://dx.doi.org/10.1093/rheumatology/keab460] [PMID:  34142111]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0118715230273701231102100558	Print ISSN 1871-5230
Publisher Name Bentham Science Publisher	Online ISSN 1875-614X

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammato ry Diseases

Graphical Abstract

Related Journals

Related Books